Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Molecular Imaging, Inc. Announces New White Paper: Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging

October 11, 2013

Molecular Imaging, a specialty contract research organization providing multi-modality preclinical in vivo imaging services to pharmaceutical and biotechnology companies, announces a new white paper to examine new imaging strategies that can facilitate the discovery and clinical use of new therapeutics and diagnostics.

Ann Arbor, MI (PRWEB) October 11, 2013

Molecular Imaging, Inc., in collaboration with Cambridge Healthtech Associates™, held a webinar, which took place on September 10, 2013 at 11am ET and featured presentations by Patrick McConville, Chief Scientific Officer of Molecular Imaging, and Maria Vosjan of BV Cyclotron VU.

Dr. McConville provided an overview of the key imaging technologies involved in dual labeling and imaging strategy, and how these technologies can be accessed and used to drive key decision-making associated with assessment of biologics targeting and biodistribution. Dr. Vosjan presented an overview of immuno-PET imaging of targeting and non-invasive biodistribution.

The findings of this webinar have been published in a white paper, "Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging."

"Molecular Imaging provides robust data for decision-making by providing molecular targeting precision, pharmacokinetics and whole body distribution through its in vivo imaging techniques," says Dr. McConville, Chief Scientific Officer/SVP.

The white paper will be available for viewing at the World ADC Conference in San Francisco, on October 14-17, 2013, where Molecular Imaging, Inc. will have an exhibitor booth.

About Molecular Imaging, Inc.

Molecular Imaging, Inc. is a specialty contract research organization (CRO) located in Ann Arbor, Michigan. Molecular Imaging employs a wide array of imaging technologies, including MRI, micro-CT, micro-PET, SPECT and optical (two-dimensional and fluorescence molecular tomography) to quantitatively assess test agent performance at anatomical, functional and molecular levels. Molecular Imaging Inc. also conducts applications research to develop and optimize the use of imaging and actively seeks collaborations to further advance imaging in the field of drug discovery.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11210703.htm


Source: prweb